# Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer

> **NCT06403878** · PHASE2 · RECRUITING · sponsor: **Sichuan University** · enrollment: 68 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Nab paclitaxel
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT06403878
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05
- **Primary completion:** 2026-05
- **Final completion:** 2026-08
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06403878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06403878, "Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06403878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*